RIPK3 mediates liver injury, inflammation, induction of hepatic progenitor cells/activated cholangiocytes and liver fibrosis.70 RIPK3 thus represents a promising target for future therapeutic strategies in patients with chronic metabolic liver disease. This evidence concerns the gene RIPK3 and Hepatic fibrosis.